tolvaptan: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
tolvaptan: clinical details
Prescribing considerations
- Initiation and supervision require expertise in ADPKD, assessment of rapid progression and understanding of hepatic risk controls.
- Ensure reliable access to water, an intact thirst response and unobstructed urinary outflow.
- Correct sodium abnormalities and volume depletion before initiation.
- Use caution with severe hepatic impairment, advanced kidney disease, diabetes, hyperuricaemia or conditions limiting fluid intake.
- Treatment is not recommended for children because safety and efficacy have not been established.
Contraindications and cautions
- Hypersensitivity to tolvaptan, excipients, benzazepine or benzazepine derivatives
- Baseline liver abnormalities meeting permanent-discontinuation criteria
- Anuria
- Volume depletion
- Hypernatraemia
- Inability to perceive or respond to thirst
- Pregnancy
- Breastfeeding
Monitoring
- Check hepatic transaminases and bilirubin before initiation, monthly for the first 18 months and every three months thereafter; interrupt promptly for symptoms or clinically significant abnormalities.
- Assess serum sodium, creatinine, electrolytes and hydration before and after initiation; continue electrolyte monitoring during long-term treatment.
- Monitor volume status and body weight; progressive weight loss may indicate dehydration.
- Assess uric acid before initiation and subsequently when clinically indicated.
- Consider urine osmolality and plasma osmolality or sodium when assessing vasopressin blockade and hydration.
Clinical pharmacology
Tolvaptan selectively antagonises renal vasopressin V2 receptors. It is rapidly absorbed, highly protein-bound and metabolised predominantly by CYP3A; its aquaretic action increases free-water clearance without directly promoting sodium excretion.
Formulation and product differences
- The selected lower-strength tablet is round and scored so it can be divided into equal halves; the higher-strength tablet is square and unscored.
- The tablets contain lactose and are essentially sodium-free.
- Store in the original package to protect from light.
tolvaptan preparations and strengths
Tablet
Route: Oral
Strengths: 7.5 mg, 15 mg, 30 mg, 45 mg, 45 mg + 15 mg, 60 mg, 60 mg + 30 mg, 90 mg, 90 mg + 30 mg
tolvaptan interactions
Check all prescribed, non-prescribed and herbal products with the specialist pharmacist or prescriber. Important examples include:
Strong or moderate CYP3A inhibitors, including clarithromycin, itraconazole, ritonavir, fluconazole, erythromycin, diltiazem and verapamil
They can substantially increase tolvaptan exposure and may require specialist adjustment or an alternative.
Grapefruit juice
It increases tolvaptan exposure and must be avoided.
Potent CYP3A inducers, including rifampicin, carbamazepine, phenytoin and St John’s wort
They can reduce tolvaptan exposure and effectiveness and should be avoided.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.